AHEAD OF THE STREET - SPECIAL REPORT AND FREE TRIAL SUBSCRIPTION !

Editors Note: A unique opportunity today allows us to present you with a special report from Ahead Of The Street, a subscription service that has agreed to offer a FREE TRIAL for our readers. We're extremely pleased to have the opportunity to pass along their thoughts on four companies that have posted substantial gains since they were picked by Ahead Of The Street, and their feature story on Astralis Ltd. (OTCBB: ASTR).

Please take a moment to read today's article below. This is a one-time opportunity to review this information and receive a Free Trial Subscription.  We think you'll find it quite interesting!
 

Business Financial Publishing has brought readers of the Growth Report these profitable investment opportunities in the past six months:	FREE TRIAL SUBSCRIPTION YES! Send me my free in-depth Special Report on Astralis Ltd.  and start my trial subscription to Ahead of the Street NOW!
Sonic Blue (SBLU:NASDAQ) picked at $1.30   high close since - $5.13 up 294% Peyto Explorations (PEY:TSE) picked at C$2.88 high close since - C$5.85 up 103% Sonic Solutions (SNIC:NASDAQ)  picked at $4.09 high close since – $7.95 up 94% Wendy's (WEN:NYSE)  picked at $26.49 high close since - $37.30 up 41% The same market-wise editorial and research team that brought Growth Report readers success is pleased to announce the release of our newly launched Ahead of the Street, with an advanced copy of our special report on a must own Biotech Investment Opportunity.
Dear Investor, Finding a new investment that has a chance to capture Wall Street’s imagination BEFORE the CEO of the Company appears on the cover of Forbes or other financial magazines is a challenge that faces all investors who purchase stocks. I invite you to read the “hot off the Ethernet” Ahead of the Street Special Report on an undiscovered biotech company that we believe could fit that tall order.  Our report for Astralis Ltd. has been researched and prepared by Ahead of the Street’s Editor-in-Chief, Kyle Maguire. Mr. Maguire and I have collaborated together at Ahead of the Street for over five years, through thick and thin markets.  I assure you he has surpassed my highest expectations with the quality of this latest full research report.  To understand the potential of this situation you must act now and read this compelling report on Astralis Ltd. (ASTR:OTCBB). Astralis is an emerging biotechnology company focusing on the research and development of novel treatments for immune system disorders and skin diseases. PsoraxineTM, Astralis’ first product candidate, is under development for the treatment of all forms of psoriasis.  Millions of Americans suffer from PSORIASIS, a very common disease affecting roughly 2.6% of the U.S. population.  According to the National Psoriasis Foundation  (NPF), at the present time only 1.6 million out of more than 7 million people in the United States seek treatment for the disease.  By 2007, the disease will grow to affect 3.7% of the U.S. population, pushing what is currently a $4.3 billion U.S. market to a $6 billion market by 2007.  Here are some important points to consider:  ·Astralis could become a leader in the field of psoriasis treatment, a $3 billion market in the U.S. alone.  ·8 years of clinical trials in Venezuela have yielded better remission rates than any other psoriasis drug currently under development.  ·Possibility that drug development could be fast-tracked in the U.S. based on existing clinical trial data.  ·Recent $20 million investment by Skyepharma PLC values Astralis at $130 million.  ·Merrill Lynch suggests that the theoretical market for Astralis’ drug, PsoraxineTM could be as high as $1 billion annually.  One of the strongest factors pointing to the company’s long-term success is that Astralis has gained a large endorsement from a half billion dollar pharmaceutical company.  Skyepharma PLC [SKYE: NASDAQ] effectively acquired a 15.3% stake in Astralis in return for staged investments of up to US$20 million, of which $12.5 million has been advanced.  Skyepharma will provide all development, pre-clinical and clinical development services for PsoraxineTM up to the completion of Phase II clinical studies. On the successful conclusion of these trials, Astralis has provided Skyepharma an option to acquire the worldwide distribution and licensing rights for PsoraxineTM.  The significance of this partnership was not lost on Merrill Lynch.  The firm commented in a recent research report, “Psoraxine is an interesting, albeit opportunistic, product opportunity for Skyepharma. Psoriasis affects up to 6 million patients in the U.S. a year and is poorly treated, with other compounds in development unlikely to provide satisfactory relief…” But don’t just take our word for it, you can read the Merrill Lynch  “More than Skin Deep” report on Skyepharma HERE. As experienced Biotech investors know, success in Phase II can mean a huge increase in market capitalization for a small company, and this is why we are so enticed by the long-term investment opportunity available in the publicly traded shares of Astralis.  We know you will take the time to complete your own due diligence on the company, and hope that our FULL RESEARCH REPORT will act as a starting point.  To read the full Ahead of the Street report, please click here.  Ahead of the Street is offering you an opportunity to receive a free in-depth Special Report for an exciting and yet undiscovered Biotech Company that we believe stands on the edge of massive success. We are certain that the quality of this report will impress you and that you will want to try a free trial subscription.  CLICK HERE TO READ THE REPORT and we’ll be busy keeping you:                                                                               Ahead of the Street!
Regards,  Ian Wyatt Publisher Ahead of the Street Business Financial Network iwyatt@bizfn.com	FREE TRIAL SUBSCRIPTION YES! Send me my free in-depth Special Report on Astralis Ltd.  and start my trial subscription to Ahead of the Street NOW!
© Copyright 2002, Business Financial Publishing LLC. All rights reserved.  IMPORTANT NOTICE AND DISCLAIMER This electronic publication is issued solely for information purposes, and does not represent an offer to sell, or a solicitation of an offer to buy, any security. The purpose of this advertisement, like any advertising, is to provide coverage and publicity for the advertising company, its products and/or services. The information provided herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation, or which would subject us to any registration requirement within such jurisdiction or country. Business Financial Publishing LLC is not a registered investment adviser, broker-dealer, or member of any financial regulatory bodies, and has not independently verified the information contained herein. While opinions and statements included herein are based on sources (including the featured companies and public sources) believed to be reliable, no warranty, express or implied, is made as to their accuracy, completeness or correctness.  As required by section 17(b) of the U.S. Securities act of 1933, as amended, Business Financial Publishing LLC hereby discloses that, as the publisher of this report, it has been paid fifty thousand dollars by Uptick Communications Group inc. As compensation for the distribution of this advertisement, and therefore cannot be considered independent.  Information within this advertisement contains "forward looking statements." any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements." "Forward looking statements "are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. You should verify all claims and do your own research before investing in any securities mentioned on this website.  Investing in securities is speculative and carries a high degree of risk. You may lose part or all of your principal investment. This advertisement may contain hyperlinks to web sites operated by third parties other than us. Such hyperlinks are provided for the reader's reference and convenience only. We are not responsible for the reliability of these external sites, nor are we responsible for any of the contents, advertising, products, or other materials on such external sites. Our inclusion of hyperlinks to such web sites does not imply any endorsement of the material on such web sites or any association with their operators. Under no circumstances are we responsible or liable, directly or indirectly, for any loss or damage caused or alleged to have been caused in connection with the use of or reliance on any content, goods, or services available on such external site. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.  We encourage our readers to invest carefully and read the investor information available at the web sites of the u.s. Securities and exchange commission (sec) at http://www.sec.gov, in particular all specific corporate disclosure found in its Edgar section and its advisory to investors concerning internet stock fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm.  The NASD has also published information on how to invest carefully at its web site at: http://www.nasd.com.

YES! Send me my free in-depth Special Report on Astralis Ltd. and start my trial subscription to Ahead of the Street NOW! (click here)

Business Financial Publishing has brought readers of the Growth Report these profitable investment opportunities in the past six months:

Sonic Blue (SBLU:NASDAQ) picked at $1.30   high close since - $5.13 up 294%

Peyto Explorations (PEY:TSE)  picked at C$2.88 high close since - C$5.85 up 103%

Sonic Solutions (SNIC:NASDAQ)  picked at $4.09 high close since – $7.95 up 94%

Wendy's (WEN:NYSE)  picked at $26.49 high close since - $37.30 up 41%

The same market-wise editorial and research team that brought Growth Report readers success is pleased to announce the release of our newly launched Ahead of the Street, with an advanced copy of our special report on a must own Biotech Investment Opportunity.

Dear Investor, 

Finding a new investment that has a chance to capture Wall Street’s imagination BEFORE the CEO of the Company appears on the cover of Forbes or other financial magazines is a challenge that faces all investors who purchase stocks. I invite you to read the “hot off the Ethernet” Ahead of the Street Special Report on an undiscovered biotech company that we believe could fit that tall order.  Our report for Astralis Ltd. has been researched and prepared by Ahead of the Street’s Editor-in-Chief, Kyle Maguire. Mr. Maguire and I have collaborated together at Ahead of the Street for over five years, through thick and thin markets.  I assure you he has surpassed my highest expectations with the quality of this latest full research report.

To understand the potential of this situation you must act now and read this compelling report on Astralis Ltd. (ASTR:OTCBB). 

Astralis is an emerging biotechnology company focusing on the research and development of novel treatments for immune system disorders and skin diseases. PsoraxineTM, Astralis’ first product candidate, is under development for the treatment of all forms of psoriasis. 

Millions of Americans suffer from PSORIASIS, a very common disease affecting roughly 2.6% of the U.S. population.  According to the National Psoriasis Foundation  (NPF), at the present time only 1.6 million out of more than 7 million people in the United States seek treatment for the disease.  By 2007, the disease will grow to affect 3.7% of the U.S. population, pushing what is currently a $4.3 billion U.S. market to a $6 billion market by 2007.  Here are some important points to consider: 

·        Astralis could become a leader in the field of psoriasis treatment, a $3 billion market in the U.S. alone. 

·        8 years of clinical trials in Venezuela have yielded better remission rates than any other psoriasis drug currently under development. 

·        Possibility that drug development could be fast-tracked in the U.S. based on existing clinical trial data. 

·        Recent $20 million investment by Skyepharma PLC values Astralis at $130 million. 

·        Merrill Lynch suggests that the theoretical market for Astralis’ drug, PsoraxineTM could be as high as $1 billion annually. 

One of the strongest factors pointing to the company’s long-term success is that Astralis has gained a large endorsement from a half billion dollar pharmaceutical company.  Skyepharma PLC [SKYE: NASDAQ] effectively acquired a 15.3% stake in Astralis in return for staged investments of up to US$20 million, of which $12.5 million has been advanced. 

Skyepharma will provide all development, pre-clinical and clinical development services for PsoraxineTM up to the completion of Phase II clinical studies. On the successful conclusion of these trials, Astralis has provided Skyepharma an option to acquire the worldwide distribution and licensing rights for PsoraxineTM. 

The significance of this partnership was not lost on Merrill Lynch.  The firm commented in a recent research report, “Psoraxine is an interesting, albeit opportunistic, product opportunity for Skyepharma. Psoriasis affects up to 6 million patients in the U.S. a year and is poorly treated, with other compounds in development unlikely to provide satisfactory relief…” But don’t just take our word for it, you can read the Merrill Lynch  “More than Skin Deep” report on Skyepharma. 

As experienced Biotech investors know, success in Phase II can mean a huge increase in market capitalization for a small company, and this is why we are so enticed by the long-term investment opportunity available in the publicly traded shares of Astralis.  We know you will take the time to complete your own due diligence on the company, and hope that our FULL RESEARCH REPORT will act as a starting point.  To read the full Ahead of the Street report, please click here.

Ahead of the Street is offering you an opportunity to receive a free in-depth Special Report for an exciting and yet undiscovered Biotech Company that we believe stands on the edge of massive success. We are certain that the quality of this report will impress you and that you will want to try a free trial subscription. 

CLICK HERE TO READ THE REPORT and we’ll be busy keeping you: Ahead of the Street!

Regards, 

Ian Wyatt
Publisher
Ahead of the Street
Business Financial Network
iwyatt@bizfn.com

FREE TRIAL SUBSCRIPTION
YES! Send me my free in-depth Special Report on Astralis Ltd. and start my trial subscription to Ahead of the Street NOW! 

© Copyright 2002, Business Financial Publishing LLC. All rights reserved. 

IMPORTANT NOTICE AND DISCLAIMER
This electronic publication is issued solely for information purposes, and does not represent an offer to sell, or a solicitation of an offer to buy, any security. The purpose of this advertisement, like any advertising, is to provide coverage and publicity for the advertising company, its products and/or services. The information provided herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation, or which would subject us to any registration requirement within such jurisdiction or country.

Business Financial Publishing LLC is not a registered investment adviser, broker-dealer, or member of any financial regulatory bodies, and has not independently verified the information contained herein. While opinions and statements included herein are based on sources (including the featured companies and public sources) believed to be reliable, no warranty, express or implied, is made as to their accuracy, completeness or correctness. 
As required by section 17(b) of the U.S. Securities act of 1933, as amended, Business Financial Publishing LLC hereby discloses that, as the publisher of this report, it has been paid fifty thousand dollars by Uptick Communications Group inc. As compensation for the distribution of this advertisement, and therefore cannot be considered independent. 

Information within this advertisement contains "forward looking statements." any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements." "Forward looking statements "are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. You should verify all claims and do your own research before investing in any securities mentioned on this website.  Investing in securities is speculative and carries a high degree of risk. You may lose part or all of your principal investment.

This advertisement may contain hyperlinks to web sites operated by third parties other than us. Such hyperlinks are provided for the reader's reference and convenience only. We are not responsible for the reliability of these external sites, nor are we responsible for any of the contents, advertising, products, or other materials on such external sites. Our inclusion of hyperlinks to such web sites does not imply any endorsement of the material on such web sites or any association with their operators. Under no circumstances are we responsible or liable, directly or indirectly, for any loss or damage caused or alleged to have been caused in connection with the use of or reliance on any content, goods, or services available on such external site. Any concerns regarding any external link should be directed to its respective site administrator or webmaster. 

We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and exchange commission (sec) at http://www.sec.gov, in particular all specific corporate disclosure found in its Edgar section and its advisory to investors concerning internet stock fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.  The NASD has also published information on how to invest carefully at its web site at http://www.nasd.com. 

Safe Harbor Statement: Statements contained in this document, including those pertaining to estimates and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. 

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  This report is for information purposes only and should not be used as the basis for any investment decision. MP has not been compensated for distribution of this report, however there may be a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934.  MP is not an investment advisor and this report is not investment advice.  This information is neither a solicitation to buy nor an offer to sell securities.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.